Key facts
- Lyv’s last known valuation is $8.3M (Sep 2022).
- It has raised $3.3M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include XAnge, Inco Ventures, Mutuelle Générale de l'Education Nationale, Future of Health Grant, Impactivist.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Lyv
- ·The full record, as it builds
Funding rounds
No funding rounds for Lyv are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lyv
Operator of a digital health therapy intended to treat long-term endometriosis effects. The company's therapy helps to reduce the symptoms of endometriosis, a gynecological, chronic, and inflammatory disease, that potentially creates very intense pelvic pain with all kinds of disorders associated with menstruation, enabling women to ease symptoms and relieve pain so that the condition does not interfere in daily life.
- Sector
- Healthcare
- HQ
- Nantes, France
- Founded
- 2021
- Employees
- 12
- Website
- lyv.app/
- Ownership
- Privately Held (backing)
Lyv doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lyv shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lyv in its N-PORT filings yet. We sweep new filings monthly.